Viracta Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2001
Revenue	0	0	0	0	2.07	Upgrade
Revenue Growth (YoY)	-	-	-	-	774.68%	Upgrade
Gross Profit	0	0	0	0	2.07	Upgrade
Selling, General & Admin	17.32	24.33	15.44	5.35	9.95	Upgrade
Research & Development	33.37	26.26	23.86	13.47	15.41	Upgrade
Other Operating Expenses	0	0	74.98	0	0	Upgrade
Operating Expenses	50.69	50.59	114.28	18.82	25.36	Upgrade
Operating Income	-50.69	-50.59	-114.28	-18.82	-23.29	Upgrade
Interest Expense / Income	3.7	0.58	0.49	0.22	0.51	Upgrade
Other Expense / Income	-3.34	-1.97	-0.01	-0.01	-0.47	Upgrade
Pretax Income	-51.06	-49.2	-114.76	-19.02	-23.33	Upgrade
Net Income	-51.06	-49.2	-114.76	-19.02	-23.33	Upgrade
Shares Outstanding (Basic)	39	38	32	0	2	Upgrade
Shares Outstanding (Diluted)	39	38	32	0	2	Upgrade
Shares Change	2.21%	18.58%	9714.39%	-86.95%	144.84%	Upgrade
EPS (Basic)	-1.32	-1.30	-3.60	-58.56	-9.38	Upgrade
EPS (Diluted)	-1.32	-1.30	-3.60	-58.56	-9.38	Upgrade
Free Cash Flow	-40.03	-35.5	-19.1	-16.11	-22.19	Upgrade
Free Cash Flow Per Share	-1.04	-0.94	-0.60	-49.61	-8.91	Upgrade
Gross Margin	-	-	-	-	100.00%	Upgrade
Operating Margin	-	-	-	-	-1123.40%	Upgrade
Profit Margin	-	-	-	-	-1125.42%	Upgrade
Free Cash Flow Margin	-	-	-	-	-1070.19%	Upgrade
EBITDA	-46.86	-48.41	-114.09	-18.77	-22.82	Upgrade
EBITDA Margin	-	-	-	-	-1100.63%	Upgrade
Depreciation & Amortization	0.49	0.21	0.18	0.03	0	Upgrade
EBIT	-47.35	-48.62	-114.27	-18.8	-22.82	Upgrade
EBIT Margin	-	-	-	-	-1100.63%	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).